Search Results
Your search for all items matches 34976 pages
Showing 4251 - 4300KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors
In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated promising clinical activity in previously treated patients with pancreatic ductal adenocarcinoma, biliary tract cancer, and other solid tumors harboring KRAS G12C mutations, according to research presented at the April...
Third-Line Treatment of Follicular Lymphoma
This is Part 3 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the third-line treatment of follicular lymphoma. The patient...
Recurrent Follicular Lymphoma
This is Part 2 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the management of recurrent follicular lymphoma. The patient...
Newly Diagnosed Follicular Lymphoma
This is Part 1 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the management of newly diagnosed follicular lymphoma. The...
Second-Line Liposomal Irinotecan Plus Fluorouracil/Leucovorin in Metastatic Biliary Tract Cancer
In an updated analysis of a Korean phase IIb trial (NIFTY) reported in JAMA Oncology, Hyung et al found that the addition of nanoliposomal irinotecan to fluorouracil and leucovorin significantly improved progression-free survival in patients with metastatic biliary tract cancer with disease...
Financial Impact on Caregivers of Spouses With Cancer
In a study reported in the Journal of Clinical Oncology, Bradley et al found that approximately one-third of caregivers of spouses with cancer reported they had stopped working and had increased household debt. In the subgroup with a lower-than-median household income, cancer caregivers were more...
Study Investigates Prevalence of ‘Low-Value’ PSA Screening for Prostate Cancer in Older Patients
In a survey study reported in JAMA Network Open, Kalavacherla et al found a high prevalence of prostate-specific antigen (PSA) screening for prostate cancer among older patients than recommended for such screening in U.S. Preventive Services Task Force guidelines. The investigators stated: “The...
Dario A. Vignali, PhD, on LAG3: The Third Checkpoint Inhibitor
Dario A. Vignali, PhD, of the University of Pittsburgh School of Medicine, discusses LAG3, the third inhibitory receptor to be used in the clinic. He describes the signaling mechanism this immunotherapy uses; new insight into its function, alone and in combination with PD-1; and an analysis of...
Jeffrey S. Weber, MD, PhD, on Melanoma: New Data on a Cancer Vaccine Combined With Pembrolizumab
Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center at New York University Langone, discusses efficacy and safety results from the phase II KEYNOTE-942 trial, which showed that a personalized mRNA-based cancer vaccine, combined with the immune checkpoint inhibitor pembrolizumab, improved...
Christina M. Dieli-Conwright, PhD, MPH, on Resistance Exercise as Medicine: Improving Health and Cancer Outcomes
Christina M. Dieli-Conwright, PhD, MPH, of Dana-Farber Cancer Institute, discusses her research on the ways in which postdiagnosis exercise, particularly resistance exercise, can build strength and muscle mass and affect cancer outcomes. She also describes her focus on biomarkers related to body...
Homage to a Giant in Hematology: The Fascinating Story of the Quest to Cure Leukemia
Bone marrow transplantation in leukemia is one of the great success stories in the history of oncology, as is that of the late Nobel Laureate E. Donnall Thomas, MD, the pioneering clinical researcher whose name is synonymous with life-saving marrow transplantation. Dr. Thomas, who was born in the...
Dabrafenib With Trametinib for Pediatric Low-Grade Glioma With BRAF V600E Mutation
On March 16, 2023, dabrafenib with trametinib was approved for pediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.1,2 The U.S. Food and Drug Administration also approved new oral formulations of both drugs suitable for patients who ...
Patricia M. LoRusso, DO, PhD (hc), Chosen as AACR President-Elect for 2023–2024
The members of the American Association for Cancer Research (AACR) have selected Patricia M. LoRusso, DO, PhD (hc), as the AACR President-Elect for 2023–2024. Dr. LoRusso became President-Elect during the AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2023 in Orlando,...
I’m BRCA-Positive and Survived Both Breast and Pancreatic Cancers
Cancer has stalked my family for generations. My mother, brother, and maternal uncle were diagnosed with melanoma. Fortunately, all survived. When my sister was diagnosed with early-stage invasive ductal carcinoma in 2010, she underwent genetic testing, which showed she was positive for the BRCA2...
ASCO Member Testifies Before Congress, Urging Significant Increase in Federal Cancer Research Funding
Brian Persing, MD, a medical oncologist and hematologist in Mobile, Alabama, and a member of ASCO, the world’s leading professional organization representing nearly 45,000 oncology professionals, testified before the House Appropriations Subcommittee on Labor Health and Human Services and...
Emerging Success With Novel Targeted Therapies in Endocrine-Resistant Metastatic Breast Cancer
In hormone receptor–positive breast cancer, the ability to successfully target key mediators of endocrine resistance is changing the outlook of metastatic disease in this subtype, according to Aditya Bardia, MD, MPH, FASCO, Director of Breast Cancer Research and Associate Professor at Harvard...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery, Medical College of Wisconsin, shared insights on the transition of circulating tumor DNA...
Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
Circulating tumor DNA (ctDNA) may transform disease monitoring and guide treatment for soft-tissue sarcomas, according to data presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Findings of a retrospective review showed that 85% of patients...
Social Drivers of Health: Grabbing the Steering Wheel
Study after study has demonstrated race-based differences in survival and other clinical outcomes for patients with cancer. But as health professionals, we are learning that these differences are less about a patient’s skin color and more about the legacy of racial inequality.1 This knowledge...
Expert Point of View: Yelena Y. Janjigian, MD
The GLOW study’s invited discussant, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, said the GLOW findings are “practice-changing,” validating that high claudin-18.2 (CLDN18.2) expression as an important biomarker in...
GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset
In the first-line setting, the monoclonal antibody zolbetuximab in combination with chemotherapy extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive, HER2-negative, locally advanced or metastatic gastric adenocarcinoma. This regimen is now positioned as a new standard of...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Vitamin D Deficiencies May Lead to Health Disparities in Black Patients With Prostate Cancer
Investigators have found that vitamin D deficiencies may contribute to more aggressive prostate cancer in Black patients at a younger age compared with White patients, according to a new study published by Siddappa et al in Cancer Research Communications. The new findings could pave the way for...
Black Patients With Cancer May Be More Likely to Experience Cardiotoxicity Following Chemotherapy
Chemotherapy may be associated with a 71% increased risk of treatment-related cardiotoxicity—including heart failure and cerebrovascular disease—among Black patients or patients of African ancestry compared with White patients, according to new findings presented by Gebeyehu et al at the American...
Extreme Poverty May Be a Key Driver for Relapse in Pediatric Patients With ALL
Pediatric patients with acute lymphoblastic leukemia (ALL) living in extreme poverty and undergoing maintenance therapy may have almost a twofold greater risk of relapse compared with pediatric patients who weren’t living in extreme poverty, according to a new study published by Wadhwa et al in...
Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma
In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...
Toripalimab Plus Chemotherapy May Improve Event-Free Survival in Resectable Stage III NSCLC
An interim analysis of the Neotorch study highlighted the potential of immunotherapy for the treatment of early-stage non–small cell lung cancer (NSCLC), according to data presented by Lu et al during the ASCO Plenary Series: April 2023 Session (Abstract 425126). The findings showed a significant...
Racial/Ethnic Disparities in Locoregional Recurrence Among Patients With Breast Cancer Treated in the TAILORx Trial
In a retrospective post hoc analysis reported in JAMA Surgery, Olga Kantor, MD, and colleagues found that locoregional recurrence was more common among Black and Asian vs White patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer in the context of similar access...
Locally Advanced High-Risk Prostate Cancer
This is Part 3 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of locally advanced high-risk...
De Novo Metastatic Hormone-Sensitive Prostate Cancer
This is Part 2 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of de novo metastatic...
Biochemical Recurrence of Prostate Cancer
This is Part 1 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss biochemical recurrence in prostate cancer. The...
R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin
R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall...
Early Trial Results Show Potential Benefits of FGFR Inhibitors and PARP/ATR Inhibitor Combinations in Multiple Tumor Types
In three new clinical trials, researchers have found that the novel fibroblast growth factor receptor (FGFR) inhibitor pemigatinib and new poly (ADP ribose) polymerase (PARP)/ataxia telangiectasia and Rad3-related (ATR) inhibitor combinations may be effective at treating patients with multiple...
Patients With Brain Metastases From Renal Cell Carcinoma May Have Distinct Immunosuppressive Tumor Microenvironment
Researchers have created the largest single-cell atlas of renal cell carcinoma brain metastases, with matched primary and extracranial metastases, which has potentially enabled them to discover key biological mechanisms contributing to an immunosuppressive tumor microenvironment in the brain...
COVID-19 Pandemic May Have Disrupted Cancer Reporting in 2020 and Beyond
Investigators have uncovered factors contributing to the COVID-19 pandemic’s destabilization of the usual patterns of cancer care, described specific ways that National Cancer Database data models were impacted by the pandemic, and offered guidance to cancer centers across the United States on how...
Highlights From the AACR Annual Meeting 2023
On this episode, we are sharing news presented during the American Association for Cancer Research (AACR) Annual Meeting, which was held earlier this month in Orlando. We feature three researchers discussing their findings in non–small cell lung cancer, early-stage breast cancer, and solid tumors...
Association of Delayed or Foregone Care Among Patients With Cancer and Patient-Clinician Identity Discordance
In a study reported in a research letter in JAMA Oncology, Patel et al found that delayed or foregone care due to patient-clinician discordance of identity (eg, race, religion, gender) was more common among patients with cancer vs noncancer controls. Approximately one-quarter of younger patients...
Sugemalimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma
In a Chinese phase II study (GEMSTONE-201) reported in the Journal of Clinical Oncology, Huang et al found that the PD-L1 inhibitor sugemalimab produced durable responses in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma. Study Details In the multicenter trial, 78...
Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Susan Halabi, PhD, and colleagues validated an overall survival prognostic model for docetaxel-naive patients with metastatic castration-resistant prostate cancer. As noted by the investigators, “We have previously developed and externally...
Study Identifies Mutations That May Be Associated With Poor Outcomes in Patients With NSCLC Treated With KRAS G12C Inhibitors
Researchers have discovered that co-occurring mutations in three tumor-suppressor genes—KEAP1, SMARCA4, and CDKN2A—may be linked with poor clinical outcomes in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) who were treated with the KRAS G12C inhibitors adagrasib or sotorasib,...
Novel CAR T-Cell Therapy Under Study in Metastatic Clear Cell Renal Cell Carcinoma
Treatment with the allogeneic chimeric antigen receptor (CAR) T-cell therapy ALLO-316 resulted in encouraging response rates and disease control rates for patients with metastatic clear cell renal cell carcinoma who did not respond to prior therapy, according to new findings presented by Srour et...
VT3989 May Be Safe, Effective in Patients With Advanced Mesothelioma and NF2-Mutant Solid Tumors
The yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD) inhibitor VT3989 may have been well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma as well as other NF2-mutated solid tumors, according to new findings presented by Yap et...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancers
In a single-institution study reported in JACC: CardioOncology, Feldman et al found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors, irrespective of tumor type. Study Details The retrospective cohort study used...
FDA Approves Polatuzumab Vedotin-piiq Plus R-CHP for Previously Untreated DLBCL–Not Otherwise Specified and High-Grade B-Cell Lymphoma
On April 19, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate polatuzumab vedotin-piiq (Polivy) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated adult patients who have diffuse large B-cell lymphoma (DLBCL)–not...
Long-Term Survival in Patients Diagnosed With Cancer During Pregnancy or Postpartum
In a Canadian population–based retrospective cohort study reported in JAMA Oncology, Cairncross et al found that patients diagnosed with cancer during pregnancy or postpartum had worse 5-year survival than those diagnosed at a time remote from pregnancy. Study Details The study included data from...
Harry Klein, PhD, on MatchMiner: An Open-Source AI Precision Medicine Trial Matching Platform
Harry Klein, PhD, of Dana-Farber Cancer Institute, discusses MatchMiner, a software platform launched in 2017, that matches patients with appropriate clinical trials of targeted therapies. The platform uses data on the genetic features of a patient’s cancer, as well as clinical data, to identify...
Karriem S. Watson, DHSc, on Early Engagement in Clinical Trials for Underrepresented Communities
Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance...
Sherry X. Yang, MD, PhD, on Breast Cancer: New Recurrence Score Data From the TAILORx Trial
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a poor prognosis. This result suggests the need to develop new management strategies for patients with ...
Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors
Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose ...
